|BioShares Biotechnology Clinical Trials -- USA Etf|| |
USD 30.55 0.05 0.16%
The organization shows Beta (market volatility) of -2.3353 which signifies that as returns on market increase, returns on owning BioShares Biotechnology are expected to decrease by larger amounts. On the other hand, during market turmoil, BioShares Biotechnology is expected to significantly outperform it.. Although it is vital to follow to BioShares Biotechnology
historical returns, it is good to be conservative about what you can actually do with the information regarding equity current trending patterns. The philosophy towards foreseeing future performance of any etf is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators
. We have found twenty-eight technical indicators
for BioShares Biotechnology Clinical Trials which you can use to evaluate performance of the entity.
BioShares Biotechnology Relative Risk vs. Return Landscape
If you would invest 2,739
in BioShares Biotechnology Clinical Trials on December 19, 2017
and sell it today you would earn a total of 316
from holding BioShares Biotechnology Clinical Trials or generate 11.54%
return on investment over 30
days. BioShares Biotechnology Clinical Trials is generating 0.562% of daily returns assuming volatility of 1.751% on return distribution over 30 days investment horizon. In other words, 16% of equities are less volatile than the company and above 90% of equities are expected to generate higher returns over the next 30 days.
Daily Expected Return (%)
Considering 30-days investment horizon, BioShares Biotechnology Clinical Trials is expected to generate 4.61 times more return on investment than the market. However, the company is 4.61 times more volatile than its market benchmark. It trades about 0.32 of its potential returns per unit of risk. The DOW is currently generating roughly 0.57 per unit of risk.
Based on latest financial disclosure the price to book indicator of BioShares Biotechnology Clinical Trials is roughly 1.75 times. This is 2.34% higher than that of the Bio Shares family, and 2.64% higher than that of Health
category, The Price to Book for all etfs is 80.41% lower than the firm.
| || BioShares Biotechnology Comparables |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
BioShares Biotechnology Daily Price Distribution
The median price of BioShares Biotechnology for the period between Tue, Dec 19, 2017 and Thu, Jan 18, 2018 is 28.73 with a coefficient of variation of 4.03. The daily time series for the period is distributed with a sample standard deviation of 1.16, arithmetic mean of 28.9, and mean deviation of 0.98. The Etf received some media coverage during the period.